Nichi-Iko rights offering to support production, biosimilar plans

The major Japanese generics firm Nichi-Iko Pharmaceutical is planning to raise an estimated JPY12.58bn ($123m) in total net proceeds from a new rights offering, with the new funds already earmarked for an array of capital investment and product development projects.